Trial Profile
A Phase IIb, Randomized, Double-blind, Multicenter, Placebo-controlled Study Evaluating the Efficacy and Safety of CT-P27 in Subjects with Acute Uncomplicated Influenza A Infection
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2022
Price :
$35
*
At a glance
- Drugs CT P27 (Primary)
- Indications Influenza A virus infections
- Focus Therapeutic Use
- Sponsors Celltrion
- 28 Oct 2022 Status changed from completed to discontinued.
- 16 Apr 2019 Status changed from recruiting to completed, as reported in an abstract presented at the 29th European Congress of Clinical Microbiology and Infectious Diseases
- 16 Apr 2019 Results assessing time to resolution of influenza symptoms and fever presented at the 29th European Congress of Clinical Microbiology and Infectious Diseases